First tranche of $15 million expected to close on March 20, 2026; second tranche of up to $15 million available, for up to $30 million in total proceeds from the sale of common stock and pre-funded ...
Gross Profit Rises 18% to $15.5 Million on 380 Basis Point Margin Expansion; Operating Expenses Cut 18% Year-Over-YearNet Loss Narrows 44% to ...
Advancing transformation into a diversified biomedical innovation company with a clear path to cash flow positiveOramed strategic transaction ...
Advancing transformation into a diversified biomedical innovation company with a clear path to cash flow positive Oramed strategic transaction receives shareholder approval- Lifeward gains new oral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results